A
Ambys Medicines
Biotech & Life Sciences · Redwood City, United States · Founded 2018
A developer of regenerative medicine therapies for serious liver diseases MoreLess
Ambys Medicines, operating under the website ambys.com, is a pioneering biotechnology startup that is revolutionizing the medical and pharmaceutical industry. The company specializes in the development of a bio-incubator that propagates high-quality primary human hepatocytes, also known as liver cells.
The company's primary clients are pharmaceutical companies and the liver research community. Pharmaceutical companies use these liver cells to test new drugs for toxicity and safety, ensuring that they are safe for human consumption. The liver research community, on the other hand, uses these cells for the development of new therapeutics for liver failure, liver disease, and rare diseases. This innovative technology also aids in the advancement of other disease-specific research.
Ambys Medicines operates in the biotechnology market, specifically in the sector of liver cell research and drug testing. Their business model revolves around the production and supply of high-quality liver cells to their clients. The company generates revenue by selling these cells to pharmaceutical companies and research institutions.
The company's success is also attributed to its strategic partnerships. These partners provide the necessary tools, information, and support needed to achieve the company's mission of developing a consistent, high-quality source of primary human hepatocytes and applying them to multiple research and clinical applications.
Keywords: Biotechnology, Pharmaceutical Industry, Liver Cells, Hepatocytes, Drug Testing, Liver Research, Therapeutics, Disease-Specific Research, Bio-Incubator, Strategic Partnerships.
Company overview
Ambys Medicines company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Redwood City, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 65.0
Valuation & funding
Ambys Medicines funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2021 | $47M | $300M | Takeda Ventures · Schroders · Alexandria Venture Investments · SmileGate Investment | ↗ |
| SERIES AOther financing | Aug 2018 | $60M | $240M | Takeda · Takeda Ventures · Third Rock Ventures | — |
| SPINOUTOther financing | Jan 2018 | $0 | — | Oregon Health & Science University · University of Illinois Urbana Champaign · University of California, San Francisco | — |
Growth signals
Ambys Medicines website traffic
Latest recorded traffic for Ambys Medicines is 120 monthly website visits, up 9.1% over the last three months. Ambys Medicines's team declined 16.7% over the past year.
Comparisons
Ambys Medicines compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Ambys Medicines's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Ambys Medicines has talent and traffic
team presence
In the news
Latest news about Ambys Medicines
Recent press, funding announcements, and product moves mentioning Ambys Medicines — open to read from the original sources.
Market sentiment
What the market is saying about Ambys Medicines
An AI-synthesized read of the highest-engagement posts about Ambys Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ambys Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.

















